CClinicalTrials.gg
Not yet recruitingNCT04660669IPAADUpdated Jun 8, 2026

Early Intervention in Remote Autism (IPAAD)

An interventional study of ESDM intervention and MOOC in Early Intervention in Remote Autism, sponsored by University Hospital, Brest. Not yet recruiting at 4 sites in France. Open to participants aged 15 Months to 36 Months. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by University Hospital, Brest · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
15 Months to 36 Months
Sex
All
01

Study summary

The Early Start Denver Model (ESDM) has shown its efficiency in the early management of ASD.

The study aims to evaluate the efficiency of a new type of management based on a semi-intensive center-based intervention (8h per week) coupled with a MOOC (Massive Online Open Course: a teaching and learning intervention based on instrumental and interactive teaching situations) for remote parental training/supervision. The goal is to determine if compared to the ESDM reference intervention (15h per week), this type of care can bring, a sufficient improvement in child development course and decreased symptoms of autism in young children, and if it could be, therefore, better suited to the needs of children and their family, bypassing the previously stated obstacles.

02

Conditions studied

  • Early Intervention in Remote Autism

Browse trials for

Keywords

  • Autism
  • ASD
  • ESDM
  • MOOC
03

In context

Autistic Disorder

1,344 studies on the registry are indexed under Autistic Disorder; 334 are open to participants now.

This study's planned enrollment of 90 is above the median of 45 across 1,044 interventional studies indexed under Autistic Disorder.

Browse Autistic Disorder studies →

Lead sponsor

University Hospital, Brest is the lead sponsor of 594 studies on the registry; 135 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Months to 36 Months
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Diagnosis of ASD based on the Diagnosis and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria;
  2. Diagnosis of ASD on the Autism Diagnosis Observation Schedule (ADOS-2) and Autism Diagnosis Interview (ADIR) for toddlers (we will include children above or equal to 13, which is the research cut-off);
  3. Aged between 15 and 36 months;
  4. DQ of 30 or above at the MSEL
  5. Sign informed consent form by both parents

Exclusion criteria

Exclusion Criteria:

  1. A neurodevelopmental disorder with known etiology (e.g. fragile X syndrome, Rett syndrom)
  2. Significant sensory or motor impairment
  3. Major physical problems such as a chronic serious health condition
  4. History of a serious head injury and/or neurologic disease
  5. Seizures at time of entry
  6. Use of psychoactive medications (7 ) Families unavailable for the intervention and the followup over a period of 12 months

(8) Impossibility for family to have access to the MOOC

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Other
    ESDM 15h

    This arm receives 15 hours per week of ESDM intervention from ESDM therapists. The parents benefit from a 20 hour parent training program delivered in the participating center.

    Other: ESDM intervention

  • Other
    ESDM 8h + MOOC

    This arm receives 8 hours per week of ESDM intervention from ESDM therapists in addition to whatever community service the parents choose. The parents benefit from a training program remotely delivered via a MOOC platform as well as parental supervision of sessions delivered at home 1 hour per week for the duration of the study.

    Other: ESDM intervention · Other: MOOC

Interventions

  • OtherESDM intervention

    Early Start Denver Model (ESDM) intervention with remote parental training/ supervision versus intensive ESDM intervention.

  • OtherMOOC

    Massive Online Open Course: a teaching and learning intervention based on instrumental and interactive teaching situations

06

What researchers measure

Primary outcomes

  1. The gain in developmental quotient measured using the Mullen Scales of Early Learning (MSEL)

    Minimum = 49 (worse outcome) and maximum = 155 (better outcome)

    Time frame: From day 0 to months 12

Secondary outcomes

  1. Assessment of child autism symptoms and change in autism symptoms using ADOS-2

    Minimum = 0 (better outcome) and maximum = 28 (worse outcome)

    Time frame: At baseline, 6 months after the set up of the intervention and at 12 months after the set up of the intervention

  2. Assessment of child behavioral adaptation using The Vineland Adaptive Behavior Scales second version (VABS-2)

    Minimum = 20 (worse outcome) and maximum = 160 (better outcome)

    Time frame: At baseline, 6 months after the set up of the intervention and at 12 months after the set up of the intervention

  3. Assessment of sensory reactivity using The Dunn's Sensory Profile for toddlers

    Minimum = 38 (worse outcome) and maximum = 190 (better outcome)

    Time frame: At baseline, 6 months after the set up of the intervention and at 12 months after the set up of the intervention

  4. Assessment of the parent burden and quality of life using the CareQuol-7D

    Minimum = 0 (worse outcome) and maximum = 100 (better outcome)

    Time frame: At baseline, 6 months after the set up of the intervention and at 12 months after the set up of the intervention

07

Study locations

4 sites
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04660669
Lead sponsor
University Hospital, Brest
Responsible party
Sponsor
First posted
Dec 9, 2020
Start date
Dec 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jun 8, 2026

Study contacts

Nathalie LAVENNE, Doctor
Contact
nathalie.lavenne-collot@chu-brest.fr
02 98 01 50 47
Adrien CLARYSSE
Contact
adrien.clarysse@chu-brest.fr
02 29 02 00 88
Nathalie LAVENNE
principal investigator · CHRU BREST

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion